at weeks 1–2, 14.29 mg/g DW (IQR: 7.89–20.49) at weeks 3–4 and 10.03 mg/g DW (IQR: 9.22–18.36) at weeks 5–6. In a previous study, high calprotectin and α1-AT levels at GI-GvHD onset ...

Are you searching for effective medications to treat 'Alpha-1 Antitrypsin Deficiency'? This comprehensive guide provides the latest information on medications-both generic and branded-that are ...

Quantification of stool alpha-1 Antitrypsin (sAAT) excretion is established for estimation of enteric protein loss and assessment of disease activity. This study is to access the feasibility of ...

Shares in Wave Life Sciences rose by 74% after it reported clinical data with a pioneering new RNA-editing therapy for alpha-1 antitrypsin deficiency (AATD). Wave claims this is the first clinical ...

Bernstein has upgraded Beam Therapeutics (NASDAQ:BEAM) to outperform from market perform, citing upcoming data on the company’s drug candidate for alpha-1 antitrypsin deficiency, or AATD.

Shares of Wave Life Sciences surged to a four-year high Wednesday after the company ... its experimental treatment in patients with alpha-1 antitrypsin deficiency. In this condition, the liver ...

Oppenheimer initiated coverage of Korro Bio (KRRO) with an Outperform rating and $155 price target The company’s Opera platform enables ...